NEUROENDOCRINE TUMOUR OF THE RECTUM

This adverse event was reported 32 times

These drugs are most commonly taken by patients reporting NEUROENDOCRINE TUMOUR OF THE RECTUM:

# Drug Count
0 LUTETIUM LU 177 DOTATATE 12
1 EVEROLIMUS 11
2 OCTREOTIDE ACETATE 10
3 EVEROLIMUS TABLETS 4
4 LANREOTIDE ACETATE 2
5 BELIMUMAB 1
6 DURVALUMAB 1
7 HYDROMORPHONE HYDROCHLORIDE 1
8 LAMOTIRIGINE 1
9 LAMOTRIGINE 1
See all common drugs associated with NEUROENDOCRINE TUMOUR OF THE RECTUM

NEUROENDOCRINE TUMOUR OF THE RECTUM is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 PEGFILGRASTIM-JMDB 1 0.0022
1 LUTETIUM LU 177 DOTATATE 12 0.0021
2 OCTREOTIDE ACETATE 10 0.0003
3 LANREOTIDE ACETATE 2 0.0003
4 EVEROLIMUS TABLETS 4 0.0002
5 EVEROLIMUS 11 0.0002
6 PALONOSETRON HYDROCHLORIDE 1 0.0002
7 PEGFILGRASTIM 1 0.0001
8 DURVALUMAB 1 0.0000
9 BELIMUMAB 1 0.0000
See all drugs enriched for association with NEUROENDOCRINE TUMOUR OF THE RECTUM

NEUROENDOCRINE TUMOUR OF THE RECTUM is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Programmed Death Ligand-1 Blocker [EPC] 1 0.0000
1 B Lymphocyte Stimulator-specific Inhibitor [EPC] 1 0.0000
2 Kinase Inhibitor [EPC] 11 0.0000
3 Leukocyte Growth Factor [EPC] 2 0.0000
4 Mood Stabilizer [EPC] 1 0.0000
5 Anti-epileptic Agent [EPC] 1 0.0000
6 GLP-1 Receptor Agonist [EPC] 2 0.0000
See all drug classes enriched for association with NEUROENDOCRINE TUMOUR OF THE RECTUM